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Background: Previous studies have shown that topical corticosteroid (TCS) use induces structural ab-
normalities of the stratum corneum (SC), resulting in permeability barrier disruption. It is well-known
that epidermal barrier perturbation induces a cytokine cascade, leading to cutaneous inﬂammation.
Accordingly, we hypothesize that barrier disruption caused by long-term TCS therapy may trigger a
cutaneous cytokine cascade, which plays an important role in withdrawal dermatitis (WD) following
discontinuation of TCS. The objective of this study was to elucidate the possible mechanism of WD.
Methods: Hairless mice were treated once daily with 0.064% betamethasone dipropionate ointment for 6
weeks. After discontinuation of TCS, we examined the transepidermal water loss (TEWL), SC lipids and
expression of the cytokines interleukin 1-alpha (IL1-a) and tumor necrosis factor-alpha (TNF-a) and their
downstream signaling pathway in the following 2 weeks.
Results: We observed upregulation of IL1-a, TNF-a, inhibitor of nuclear factor kappa-B kinase subunits
alpha and beta (IKK1, IKK2) and nuclear factor kappa-B (NF-kB) in the epidermis, accompanied by a
signiﬁcantly higher TEWL after TCS cessation. These cytokines gradually disappeared with concomitant
normalization of TEWL after 1 week. Only negligible amounts of the aforementioned cytokines were
observed in the dermis. Furthermore, concurrent application of petrolatum during TCS treatment
decreased barrier impairment and production of cytokines.
Conclusion: An epidermis-derived cytokine cascade was observed following TCS-induced barrier
disruption, which is similar to that from permeability barrier insults by acetone or tape stripping. The
study suggests that concurrent application of skin care products during TCS treatment improves barrier
homeostasis, and should become a standard practice to alleviate TCS-induced WD.
Copyright © 2015, Taiwanese Dermatological Association.
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Topical corticosteroid (TCS) use is one of the most efﬁcient thera-
peutic anti-inﬂammatory modalities in dermatology. However,
cessation of TCS after long-term treatment may induce rebound
ﬂare, which is a troublesome, recalcitrant, and adverse event
frequently observed in clinical practice. Rebound ﬂare takes the
form of a rapidly evolving dermatitis with intense redness, scaling,
crusting, pustulation, and dryness of skin, occurring approximatelyier Taiwan LLC. All rights reserved.
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not only in patients with predisposing cutaneous disorders,2,6 but
also in normal skin after cessation of long-term TCS treatment.1,7
Many confusing names describe such types of TCS-induced
ﬂare-up inﬂammation, including rebound phenomenon, steroid
rosacea,8 steroid dermatitis resembling rosacea,5 steroid-induced
rosacea-like dermatitis,4,9 steroid-withdrawal rosacea-like derma-
titis,10 steroid-induced rosacea,11 and steroid addiction.12 To our
understanding, “rebound ﬂare” describes the exacerbation of the
original unresolved inﬂammatory diseases (for example, psoriasis,
atopic dermatitis, and chronic hand eczema), which are tempo-
rarily suppressed but recur after cessation of therapy. However,
long-term application of TCS induces a different type of skin
inﬂammation in both lesion and even the normal skin. This
inﬂammation is an entirely new manifestation not associated with
the original disease. To distinguish this distinct syndrome from
“rebound ﬂare”, we propose to use the term “TCS-induced with-
drawal dermatitis” (WD), which is induced by TCS and not associ-
ated with the original diseases. In the present work, we focus on
WD, instead of the rebound ﬂare of the original disease.
The mechanism of WD remains uncharacterized. Rapaport
et al13,14 believed that its clinical presentations are caused by
compensatory vessel dilatation, because prolonged vessel
constriction is induced by unbalanced nitric oxide, which is trig-
gered by TCS. However, the treatments for dilated blood vessels are
not effective. In addition, topical calcineurin inhibitors have been
reported to ameliorate symptoms of WD.15e17 Controversially,
recent studies showed that application of topical calcineurin in-
hibitor may be a potential cause of rosaceiform dermatitis.18e20 To
date, the gold-standard treatment forWD has not been established.
TCS use, both short-term and long-term, profoundly interferes
with barrier maturation processes (for examples, DNA synthesis,
mitotic rate, lipid synthesis, keratinocyte differentiation, and
lamellar body formation), thereby resulting in permeability barrier
disruption and decrease in water content of the stratum corneum
(SC), especially with mid- or high-strength TCSs such as betame-
thasone dipropionate.2,3,21e23 Inhibition of sebocytes by TCS also
contributes to the decreased water content (WC) of the SC.24
Elias et al25e27 provided clear concepts of a linkage between
disturbances in epidermal barrier function and a cytokine cascade
causing cutaneous inﬂammation. Cutaneous barrier perturbation
by tape stripping or acetone treatment induces upregulation of
mRNA and protein levels of interleukin 1-alpha (IL1-a), IL1-b, tu-
mor necrosis factor-alpha (TNF-a) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) in epidermis, aimed at
normalizing SC function.25,28 Minor barrier perturbations remain
localized to the epidermis and modulate the repair process, while
repeated or severe barrier disruption results not only in the desired
barrier repair, but also in inappropriate responses in the subjacent
dermis and endothelium. The barrier disruption-related cytokine
cascade further stimulates chemokine and intracellular adhesion
molecule (ICAM) formation and Langerhans cell activation, which
in turn produce downstream paracrine effects, leading to trapping
of circulating inﬂammatory cells in the dermis, melanocyte acti-
vation, angiogenesis, and ﬁbroplasias.26 The elicitation of inﬂam-
mation induces epidermal hyperplasia and abnormal
keratinization, leading invariably to the production of an intrinsi-
cally inferior SC, thus creating a vicious cycle of events unless the
barrier function is competent.26,29 Furthermore, the extent of the
enhanced cytokine synthesis is proportional to the degree of barrier
disruption. None of these changes have been observed in in-
dividuals who have undergone limited tape stripping, which has
not perturbed the barrier function.30
It is known that skin barrier perturbation independently induces
an epidermis-initiated inﬂammation.25,27,28 TCS-induced skinbarrier perturbation may trigger an inﬂammatory cytokine change,
which could be masked by the anti-inﬂammatory action of TCS but
becomes obvious after stopping TCS. Thereforewe hypothesize that
the barrier disruption caused by long-term TCS therapy triggers a
cutaneous cytokine cascade, which plays a vital role in WD
following discontinuation of TCS. In this study, we developed an
animal model of WD using hairless mice to observe pathologic and
molecular changes after cessation of long-term TCS. We further
investigated whether early intervention with concurrent applica-
tion of skin barrier replenishment might ameliorate WD.
Materials and methods
Animals
All experiments were performed on hairless SKH-hr1 mice (6e8
weeks old, female, purchased from Charles River Laboratories,
Wilmington, MA, USA). An approved protocol for animal use from
the Institutional Animal Care and Use Committee (IACUC) of the
National Cheng-Kung University (Tainan, Taiwan) was followed.
Treatment protocol
In two groups of animals, 25 mg of 0.064% betamethasone dipro-
pionate ointment (BDO; Septon, Shionogi& Co., Ltd., Taiwan) or the
vehicle ointment alone was applied to the lower back of each
mouse once a day for 6 weeks. Another group was assigned
petrolatum co-application treatment, where the mice were topi-
cally treated at the same site with petrolatum 12 hours after each
treatment of BDO.
Measurement of transepidermal water loss
Transepidermal water loss (TEWL) was measured by a commercial
Tewameter TM210 (Courageþ Khazaka GmbH, Cologne, Germany),
in an air-conditioned roomwith the relative humidity varying from
40% to 60% and the temperature kept constant at 20 ± 2C. Themice
were anesthetized by means of intraperitoneal injection of 4%
chloral hydrate. No topical agent was applied to the area of mea-
surement for 24 hours prior to the measurement.
Tissue examination
The full-thickness skin from the lower one-third of the back was
harvested immediately after the mice were sacriﬁced at indicated
times following cessation of application of BDO. Two skin strips
from the central area of each specimen were taken. One strip was
snap-frozen for Nile red staining. The other strip was ﬁxed in 4%
paraformaldehyde solution and embedded in parafﬁn for further
examination.
Acute barrier perturbation by tape stripping
Acute barrier disruption of the skin of a group of mice was carried
out by repeated applications of cellophane tape (5e8 times) to
remove layers of the SC to serve as a positive control. The procedure
was terminated when the TEWL reached a 2- to 3-fold increase (or
30 mg/cm2/h). The full thickness of skin was harvested 24 hours
after tape stripping.
Nile red staining for SC neutral lipids
Nile red ﬂuorescence staining was used to quantify and determine
the localization of SC neutral lipids.31 A stock solution of Nile red
(500 mg/mL) in acetone was prepared and stored at 20C,
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by the addition of 20 mL of the stock solution to 1 mL of glycerol
(75%), followed by a brief vortex to mix. To stain frozen sections of
tissue (5 mm thickness), one drop of the glycerol staining solution
was added to each section. After 10minutes at room temperature in
darkness, the sections were examined using a ﬂuorescence micro-
scope (Olympus BH-2; Olympus, Tokyo, Japan), utilizing 455 nm
and 530 nm excitation and emission frequencies, respectively.
Neutral lipidswere visualized as yellow-gold ﬂuorescent structures.
Generation of complementary RNA probes and in situ
hybridization
Total RNAwas isolated from the epidermis of hairlessmice 24 hours
after tape-stripping, by using TRIzol reagent (Invitrogen, Life
Technologies, Austin, TX, USA). Two micrograms of total RNA was
reverse-transcribed. Single-stranded, digoxigenin-labeled TNF-a,
IL-1a and inhibitor of nuclear factor kappa-B kinase subunit beta
(IKK2) cRNA probes were generated using two-step PCR ampliﬁ-
cation and in vitro RNA transcription. The primer pairs used are
listed in Table S1. Brieﬂy, 38 cycles of ampliﬁcation under standard
conditions were performed using the primer pairs (sense and
T7þantisense). The puriﬁed PCR product was further ampliﬁed
using the sense primer and composite T7 universal primer to
extend and complete the full-length 23 bp T7 promoter. One
microgram of the puriﬁed secondary PCR products served as a
template for RNA transcription using a DIG RNA Labeling Kit (Roche,
Basel, Switzerland). A sense cRNA probe was generated for negative
controls. Parafﬁn-embedded specimen sections on microscope
slides were deparafﬁnized and rehydrated in xylene and serial
concentrations of ethanol. After prehybridizing with DIG Easy Hyb
buffer (Roche) at 42C for 1 hour, the slides were incubated with
DIG-labeled cRNA probes at 42C overnight. After hybridization, the
slides were washed with 0.1 saline sodium citrate buffer (SSC) at
42C for 1 hour to remove the unhybridized probes. The sections
were incubated with anti-digoxigenin antibody conjugated with
alkaline phosphatase (Roche) for 1 hour at room temperature and
the signal was detected with nitro-blue tetrazolium/5-bromo-4-
chloro-3-indolyl-phosphate (NBT/BCIP) stock solution (Roche).
Immunohistochemical staining for TNF-a, IL-1a, IKK-1, IKK-2,
NF-kB and Ki-67
Cryostat sections (5 mm thickness) were mounted on poly l-lysine
(Sigma-Aldrich, St. Louis, MO, USA)-treated glass slides. After
quenching the endogenous peroxidase activity by using 3% H2O2 in
methanol for 5 minutes, the tissue sections were blocked with
antibody diluents (Dako Cytomation, Carpinteria, CA, USA) and
incubated with appropriate dilutions of anti-TNF-a, anti-IL-1a
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-IKK-1, anti-
IKK-2, anti-nuclear factor kappa B (NFkB p65; Abcam, Cambridge,
UK) and anti-Ki-67 (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
antibodies at room temperature for 1 hour. The slides were then
incubatedwith biotinylated secondary antibody (Dako Cytomation)
for 30 minutes at room temperature. After incubation with
streptavidin-horseradish peroxidase (HRP) reagent (Dako Cyto-
mation) for 30 minutes, the skin sections were incubated with
aminoethylcarbazole solution (Dako Cytomation) for 15e30 mi-
nutes at room temperature. An Olympus DP50 light microscope
was used to examine the skin sections.
Western blot analysis
Skin sections were separated into epidermal and dermal layers by
heating to 60C for 55 seconds and the layers were individuallyexamined. Protein was extracted using T-PER solution (Pierce
Biotechnology, Waltham, MA, USA) and the protein concentration
was measured using a Micro-BCA protein assay kit (Pierce). Elec-
trophoresis of 200 mg of total protein was carried out on a 10e15%
gradient sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel
and was transferred onto polyvinylidene diﬂuoride (PVDF) mem-
brane (PerkinElmer, Waltham, MA, USA). After blocking in 5%
nonfat milk, the membrane was incubated with anti-TNF-a (1:100;
Santa Cruz Biotechnology, Inc.), anti-IL-1a (1:500; R&D Systems,
Inc., Minneapolis, MN, USA), anti-NFkB p65 (1:1000; Abcam) and
anti-a-tubulin (1:20,000, Sigma-Aldrich) antibodies at 4C over-
night. Antibody binding was probed with peroxidase-coupled
secondary antibodies and then detected by enhanced chem-
iluminescence (Amersham, Buckinghamshire, UK).
Statistical analyses
All data were expressed as mean ± standard deviation (SD). Sta-
tistical analysis was performed by using paired and unpaired Stu-
dent t-test measures between two groups. A p value < 0.05 was
considered statistically signiﬁcant.
Results
Skin permeability was disrupted by long-term TCS and
gradually recovered after cessation of TCS
TEWL, representing an insideeoutside permeability function, was
signiﬁcantly increased by a 6-week treatment of 0.064 % BDO, and
was not affected by the vehicle (Figure 1A). TCS application was
then stopped, and TEWL continued increasing until PS5D (post-
steroids 5th day), and subsequently returned to normal by PS7D.
Neutral lipids existing in the intercellular space of the SC pro-
vide a permeability barrier to prevent water loss. Nile red is a
sensitive method to visualize and semi-quantify the lipid deposi-
tion in both physiological and pathological SC.31 Normal skin
showed abundant ﬂuorescent, horizontal staining in SC, and the
TCS treatment decreased the ﬂuorescence density in SC (Figure 1B).
Neutral lipids in SC gradually increased and then recovered to
normal level 7 days after cessation of TCS (Figure 1B).
Cessation of long-term TCS initiated upregulation of IL1-a and
TNF-a, in the epidermis (keratinocytes), but not in the dermis,
and activated their downstream effecter signals (IKK1 and
IKK2)
Long-term TCS caused signiﬁcant epidermal atrophy (Figure 2).
After cessation of TCS, expression of Ki-67, a marker of cells un-
dergoing proliferation, increased as early as PS1D. The thickness of
the epidermis increased and became morphologically similar to
rebound hyperplasia without obvious dermal inﬂammatory inﬁl-
trate up to PS7D. Both the epidermal thickness and Ki-67 expres-
sion returned to normal on PS14D.
In situ hybridization of mRNA and immunohistochemical (IHC)
staining of protein were performed to examine barrier disruption-
related cytokine changes. The mRNAs of TNF-a, IL1-a and IKK-2
were markedly upregulated in the epidermis on PS3D and subse-
quently declined to normal range by PS14D (Figure 3). Meanwhile,
IHC staining of TNF-a, IL1-a and their downstream effectors, IKK-1
and IKK-2, showed signiﬁcant upregulation in the epidermis on
PS3D, which gradually disappeared by PS7D (Figure 4). Only
negligible amounts of cytokine mRNAs and inﬂammatory cells
were present in the dermis.
Thereafter, Western blot analysis for IL1-a and TNF-a protein
expression in the epidermis and dermis were performed separately.
Figure 1 (A) Cutaneous permeability barrier (represented by TEWL) was impaired after 6 weeks of topical 0.064% betamethasone dipropionate ointment (BDO) treatment. The
barrier function gradually recovered 7 days (PS7D) after stopping topical corticosteroid (TCS) treatment. (B) As demonstrated by Nile red staining, the neutral lipid expression in the
stratum corneum (SC) diminished after long-term TCS treatment and recovered after cessation of TCS. **p < 0.05, n ¼ 5. ***p < 0.01, n ¼ 5. N ¼ normal skin; PS1e7D ¼ post-steroids
1st to 7th days; PV1D ¼ 1 day after stopping topical vehicle; TEWL ¼ transepidermal water loss. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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(data not shown). In contrast, IL1-a and TNF-a proteins in the
epidermis increased by PS2D, were signiﬁcantly upregulated at
PS3D, subsequently peaked at PS5D and declined by PS7D
(Figure 5). These sequential results corroborated the IHC ﬁndings
(Figure 4). Based on these results, it is concluded that the cytokine
cascade was mainly derived from keratinocytes, but not from in-
ﬂammatory cells.
Translocation and activation of NF-kB were signiﬁcantly
enhanced after cessation of TCS
In normal mouse skin, only weak expression of NF-kB appeared in
scattered basal keratinocytes. Acute barrier disruption by tape
stripping resulted in prominent activation and translocation of NF-
kB from the cytosol to the nucleus in both basal and suprabasal
keratinocytes of the epidermis (Figure 5A). After cessation of TCS,
NF-kBwas signiﬁcantly activated in the keratinocytes of all layers of
the epidermis by PS3D and subsequently declined. It is known that
TCSs exert their anti-inﬂammatory effects by interfering with NF-
kB. However, NF-kB was activated early in WD. Western blot ana-
lyses revealed a similar sequential expression of NF-kB (Figure 5B).
Co-application of petrolatum diminished barrier disruption
during TCS treatment, and decreased cytokine cascade after
cessation of TCS
After 6weeks of TCS treatment, the increase in TEWLwas less when
co-applied with petrolatum than in the TCS-only group (Figure 6A).Three days after cessation of all topical agents, neutral lipids of SC
were more abundant in the petrolatum co-application group
(Figure 6B). Moreover, IHC staining revealed that co-application of
petrolatum signiﬁcantly reduced the expression of TNF-a, IL-1a,
and IKK2 on PS3D (Figure 6C).
Discussion
It is intriguing that cessation of TCS triggers an entirely new and
distinct type of inﬂammation, WD, while TCS use suppresses the
original inﬂammatory process. In this study, we demonstrated that
long-term application of TCS caused barrier defects in hairless mice.
Moreover, discontinuation of TCS after long-term treatment resul-
ted in a keratinocyte-derived cytokine cascade, which was similar
to the characteristic reactions of acute barrier disruption.25 Disap-
pearance of these cytokines in the epidermis is accompanied by the
normalization of TEWL one week after stopping TCS.
TCS use inevitably causes skin barrier dysfunction in both short-
term and long-term applications, by profoundly affecting
epidermal terminal differentiation and SC formation.2,3,21e23,32,33
The disrupted skin barrier, in turn, causes a cytokine cascade
derived from keratinocytes and subsequently induces clinical
inﬂammation.
We propose a possible mechanism of TCS-related withdrawal
dermatitis and rebound phenomenon (Figure 7). TCSs exert anti-
inﬂammatory effects to suppress the inﬂammatory skin dermato-
ses. Some of the inﬂammatory skin diseases (for examples: psori-
asis vulgaris, atopic dermatitis) are only temporarily suppressed by
TCS and relapse after cessation of TCS. Conversely, many of the
Figure 2 The epidermis appeared atrophic after 6 weeks of 0.064% betamethasone dipropionate ointment (BDO) application, became hyperplastic on PS7D, and returned to
baseline on PS14D. Increase in proliferation marker (Ki-67) was noted as early as on PS1D. In-situ mRNA hybridization demonstrated increased expression of TNF-a, IL1-a and IKK2
in the epidermis on PS3D and subsequently normalization on PS14D. H&E ¼ hematoxylin and eosin; IKK2 ¼ inhibitor of nuclear factor kappa-B kinase subunit beta; IL1-
a ¼ interleukin 1-alpha; N ¼ normal skin; PS1e14D ¼ poststeroids 1st to 14th days; TNF-a ¼ tumor necrosis factor-alpha.
Figure 3 Immunohistochemical staining demonstrated increased TNF-a, IL1-a, IKK1 and IKK2 expressions in the epidermis on PS3D and PS5D, and normalization on PS7D. IKK1/
2 ¼ inhibitor of nuclear factor kappa-B kinase subunit alpha/beta; IL1-a ¼ interleukin 1-alpha; N ¼ normal skin; PS1e7D ¼ poststeroids 1st to 7th days; TNF-a ¼ tumor necrosis
factor-alpha.
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Figure 4 In accordance with the results obtained from immunohistochemical staining, Western blot analyses also demonstrated signiﬁcant upregulation of epidermal TNF-a and IL-
1a expression on PS3D and PS5D following 6 weeks of 0.064% betamethasone dipropionate ointment (BDO) treatment. The epidermis after tape-stripping served as a positive
control. *p < 0.05, n ¼ 4. **p < 0.01, n ¼ 4. IL1-a ¼ interleukin 1-alpha; N ¼ normal epidermis protein; PS1e7D ¼ poststeroids 1st to 7th days; TS ¼ tape-stripped epidermis; TNF-
a ¼ tumor necrosis factor-alpha.
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is caused by a different process. TCSs profoundly interfere with the
differentiation processes of keratinocytes and thematuration of the
skin permeability barrier, thereby resulting in barrier perturbation.
The disrupted barrier tends to initiate a keratinocyte-derived in-
ﬂammatory cascade to compensate for and repair the defected
barrier function, while TCSs mask and temporarily suppress this
type of inﬂammation. After cessation of TCS, the barrier disruption
induces the release of many kinds of cytokines, including TNF-a and
IL-1a, and promotes subsequent activation of the IKK complex
which includes IKK1/2. The downstream signaling further activatesFigure 5 Skin barrier disruption induced translocation of NF-kB from cytosol to nucleus i
ointment (BDO) treatment, positive immunohistochemical nuclear staining were observed in
The arrow indicates the translocation of NF-kB into the nucleus. (B, C) The relative expressio
after tape stripping served as a positive control. *p < 0.05, n ¼ 3. N ¼ normal skin; NF-kB ¼
stripped epidermis.the NF-kB pathway. If the barrier disruption exceeds the threshold
below which the early cytokine cascade fails to repair barrier
disruption promptly, the increased epidermal TNF-a and IL-1a will
result in recruitment of inﬂammatory cells to the dermis.26 The
subsequent mononuclear cell inﬁltrate in the dermis is likely to
produce more inﬂammatory cytokines which further aggravate the
WD, compromise the barrier repair process, and consequently
cause the clinical presentations of WD. In our experiments, we
demonstrated the increased epidermal TNF-a, IL-1a and IKK1/2 and
concurrent elevated TEWL after cessation of long-term TCS. By
PS3D, while TEWL had increased signiﬁcantly, dermal expression ofn epidermal keratinocytes. (A) After 6 weeks of 0.064% betamethasone dipropionate
the epidermal keratinocytes as early as on PS1D and became more prominent on PS3D.
n of NF-kB by Western blot examinations showed similar serial changes. The epidermis
nuclear factor-kappa B p65 subunit; PS1e7D ¼ poststeroids 1st to 7th days; TS ¼ tape-
Figure 6 Co-application of petrolatum during topical corticosteroid (TCS) treatment improved the epidermal permeability barrier as demonstrated by the examination of (A)
transepidermal water loss (TEWL) and (B) stratum corneum (SC) neutral lipids by Nile red stain on PS3D. (C) Immunohistochemical staining also demonstrated attenuation of the
barrier disruption-related cytokines cascade in the epidermis with petrolatum and TCS combined treatment on PS3D. *p < 0.05, S versus SþP, n ¼ 3. IKK2 ¼ inhibitor of nuclear
factor kappa-B kinase subunit beta; IL1-a ¼ interleukin 1-alpha; N ¼ normal control; S ¼ TCS once daily for 6 weeks; S þ P ¼ Alternating application of TCS and petrolatum in the
interval of 12 hours for 6 weeks; TNF-a ¼ tumor necrosis factor-alpha.
Figure 7 Proposed mechanisms of topical corticosteroid (TCS)-related withdrawal dermatitis (WD) and rebound phenomenon (RP). Besides the therapeutic effect of TCS use in
reducing cutaneous inﬂammation, it also inhibits the proliferation and differentiation of keratinocytes, thus interfering with the terminal differentiation processes of the epidermis.
This results in decreased physiological lipids (ceramide, free fatty acid and cholesterol), proﬁlaggrin/ﬁlaggrin (PF/F), and corniﬁed envelope (CE) formation, and ﬁnally perturbs the
epidermal barrier function. Inhibition of sebocytes also contributes to the decreased water content (WC) of stratum corneum (SC). The disrupted barrier tends to initiate a
keratinocyte-derived cytokine cascade and is relevant to the inﬂammatory cutaneous reaction of WD during and after discontinuation of TCS treatment. However, RP following
discontinuation of TCS treatment may be the combination of WD with recurrence of the original cutaneous disorders, such as psoriasis vulgaris and atopic dermatitis. As a result,
TCS acts as a double-edged sword in chronic inﬂammatory cutaneous disorders. It reduces cutaneous inﬂammation, but at the same time, through barrier disruption, TCS induces
another dermatitis (WD). The severity of WD is proportional to the degree of barrier disruption. Since the barrier defects play an important role in the TCS-induced WD, co-
application of petrolatum during TCS treatment or after discontinuation of TCS improves the barrier function and decreases the severity of WD and RP. ACD ¼ allergic contact
dermatitis; C ¼ cholesterol; CER ¼ ceramide; FFA ¼ free fatty acid; IKK ¼ inhibitor of nuclear factor kappa-B kinase; IL1-a ¼ interleukin 1-alpha; INVOL ¼ involucrin; NF-
kB ¼ nuclear factor kappa B; NMF ¼ natural moisturizing factor; TCS ¼ topical corticosteroid; TNF-a ¼ tumor necrosis factor alpha; WC ¼ water content.
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epidermal expression of TNF-a and IL-1a. The results suggest that
the impaired barrier function of WD is more related to increased
expression of TNF-a and IL-1a in the epidermis rather than in the
dermis. In the murine model, the WD skin recovered within one
week of cessation of TCS. However, in the clinical observation, it
seemed to take a longer time for human skin to recover from WD,
the prolonged recovery time in humans probably related to the
complicated daily exposure of human skin or simply species dif-
ference between human and murine, which has not yet been
investigated thoroughly.
However, it is worth noting that the detailed signaling path-
ways underlying epidermal barrier defects and acute cutaneous
inﬂammation following TCS treatment are still not fully under-
stood. Recently, studies have demonstrated that local glucocorti-
coid production (such as cortisol) and glucocorticoid receptor (GR)
signaling play important roles in skin barrier homeostasis in
normal or stressed conditions.34e37 It is possible that TCS appli-
cation will alter local expression of cortisol, 11b-hydroxysteroid
dehydrogenase 1 (11b-HSD1), or GR in the epidermis, and ulti-
mately trigger skin barrier defects and acute inﬂammatory re-
sponses of the epidermis. Therefore, in order to answer these
questions, future study should target the complex interactions of
GR, 11b-HSD1, and signaling pathways during application and after
cessation of TCS.
So far, efforts to dissociate the side effect of skin barrier
perturbation from anti-inﬂammatory activity during TCS treatment
by modiﬁcation of the drug structure or formulation has not been
successful. Moreover, it is noteworthy that many inﬂammatory skin
diseases, such as psoriasis,38 atopic dermatitis,39 and irritant con-
tact dermatitis, are associated with underlying skin barrier
dysfunction.
Treatment for WD requires discontinuation of all TCS; however,
avoidance of TCS use usually leads to further aggravation of
symptoms. Although WD spontaneously resolves several weeks
later without treatment,40 many patients resume TCS treatment to
suppress this undesirable syndrome and thus become virtually
dependent on the application of corticosteroids. This type of ﬂare
remains a recalcitrant problem.
To prevent WD as well as disease ﬂare-up, early replenishment
of topical agents to improve barrier function should become a
standard practice during and after TCS treatment, both for treating
the defective barrier due to the original dermatitis and for pre-
venting possible new barrier abnormalities induced by TCS appli-
cation. It has been demonstrated that petrolatum can be absorbed
into the outer layer of the SC, reducing the barrier defects and
accelerating barrier repair after disruption by tape stripping and
detergents.41 The barrier repair effect of petrolatum is attributed to
enhancement of SC lipid formation. Our results showed early
application of petrolatum reduces skin barrier disruption, as well as
the inﬂammatory changes after discontinuation of TCS, suggesting
the beneﬁcial role of petrolatum in preventing or decreasing the
barrier disruption due to long-term TCS treatment. Furthermore,
duringWD, petrolatum can also improve the recovery of the barrier
function and reduce disease severity.6 It was also reported that
physiological SC lipids supplemented at an optimal combination
(cholesterol, ceramide, and fatty acid in the ratio of 3:1:1) can
reverse the TCS-induced abnormalities in permeability barrier ho-
meostasis.21 Recent studies have also demonstrated that co-
application of pseudoceramide-containing physiological lipid
mixture (multi-lamellar emulsion) minimizes TCS-induced barrier
impairment.42e44 Moreover, topical treatment with PPARs or LXR
activators improve the TCS-induced abnormalities in proliferation,
differentiation, and permeability barrier function in murine
epidermis.45 The beneﬁcial effects of optimal combination therapy,and prophylactic effects to WD by these compounds (i.e., petro-
latum, physiologic SC lipids, or PPARs / LXR activators) areworthy of
further investigation.Acknowledgments
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